General Information of This Metabolic Reaction (MR) (ID: MR010784)
Formula
SVG example
Unclear
Reactant Zanubrutinib Product Zanubrutinib Metabolite M5
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010783 Zanubrutinib Zanubrutinib Metabolite M6 Unclear - Unclear zanubrutinib [1]
MR010781 Zanubrutinib Zanubrutinib Metabolite M7/M8 Unclear - Unclear zanubrutinib [1]
MR010776 Zanubrutinib Zanubrutinib Metabolite M9 Unclear - Unclear zanubrutinib [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010792 Naloxone Naloxone Metabolite M5 Unclear - Unclear Naloxone [2]
MR013820 Oxycodone Oxymorphone Unclear - Unclear Oxycodone [3]
MR001884 Oxycodone hydrochloride Oxymorphone Oxidation - O-Demethylation Oxycodone hydrochloride [4], [5], [6], [7]
MR001905 Oxymorphone Oxymorphone Oxidation - O-Demethylation Oxymorphone [8]
References
1 In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
2 Optimization of Mass Spectrometry Imaging for Drug Metabolism and Distribution Studies in the Zebrafish Larvae Model: A Case Study with the Opioid Antagonist Naloxone
3 Metabolism and Disposition of Prescription Opioids: A Review
4 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
5 Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward. J Pharmacol Exp Ther. 2022 Aug;382(2):167-180. doi: 10.1124/jpet.122.001217.
6 Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J. 2022 Feb;22(1):25-32. doi: 10.1038/s41397-021-00253-5.
7 Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery. Ann Transl Med. 2022 Dec;10(23):1262. doi: 10.21037/atm-2022-58.
8 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.